Citations

Clear

6273 citation(s) found for "To, Andrew".

REVIEW ■ : Molecular Basis of Congenital Myasthenic Syndromes: Mutations in the Acetylcholine Receptor
Engel, Andrew G. , Ohno, Kinji , Milone, Margherita , Sine, Steven M. , Wang, Hailong

Mayo Clinic

The Neuroscientist | March 17, 2007 | Volume: 4 | Issue: 3 | Pages: 185-194

10.1177/107385849800400314 Get It

The congenital myasthenic syndromes include end-plate (EP) acetylcholinesterase deficiency, presynaptic abnormalities affecting the evoked release or size of transmitter quanta, and acetylcholine (ACh) receptor (AChR) channelopathies stemming from a kinetic abnormality and/or deficiency of AChR. A kinetic abnor mality predicts, and AChR deficiency may predict, one or more mutations in an AChR subunit gene. These clues have led to the identification of 53 mutations in different subunits of AChR in 55 kinships of the congenital myasthenic syndromes. The mutations either increase or decrease the response to ACh, produce AChR deficiency, or both. In the slow-channel syndromes, prolonged opening episodes of AChR cause cationic overloading of the EP and an EP myopathy; the mutations occur in different subunits and different domains of the subunits and have dominant positive effects. The M1 and M2 mutations slow channel closure, increase apparent affinity for ACh, and variably enhance desensitization, and the extracellular αG153S enhances affinity for ACh, promoting reopening of the diliganded receptor. In the low-affinity fast-channel syndrome, εP121L reduces affinity for ACh and reopening of the diliganded receptor, resulting in a de creased response to ACh and shorter burst durations. Severe EP AChR deficiency results from heterozy gous or homozygous mutations that terminate translation prematurely; these are concentrated in the ε subunit, probably because substitution of the fetal γ for the adult ε subunit can rescue the phenotype from fatal null mutations in ε. Variable AChR deficiency and variable functional abnormalities stem from hetero allelic nonsense and missense mutations in AChR subunit genes. NEUROSCIENTIST 4:185-194, 1998
Medical Condition Is Related to Treatment Preference in Cancer Patients: Implications for Quality Assessment
Rohrer, James E. , Lim, Seah H. , Bock, Frank Andrew

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | March 8, 2007 | Volume: 24 | Issue: 1 | Pages: 36-41

10.1177/1049909106295384 | PMID 17347503 Get It

Ongoing communication with cancer patients about their treatment preferences is important. A survey assessing treatment preferences was distributed to 100 cancer patients who were newly diagnosed, 100 in remission after therapy, and 60 who had failed therapy/ relapsed; 100 cancer caregivers, and 100 noncancer patients attending the cancer center for benign hematologic problems. Almost 59% of respondents preferred treatment even if the chance of cure was less than 10%. Among subjects who did not have cancer, less than 50% wanted treatment under these circumstances, whereas over 70% of cancer patients who had failed treatment or relapsed wanted treatment ( P = .0994). Multiple logistic regression analysis revealed that the adjusted odds of preferring aggressive treatment were less for those without cancer and those with newly diagnosed cancer than for respondents who had failed treatment or were in relapse. The preference for aggressive cancer treatment is related to medical condition.
Fish oil supplementation in type 2 diabetes: a quantitative systematic review.
Wollan, Peter C. , Montori, Víctor M. , Farmer, Andrew A. , Dinneen, Seán F.

Mayo Clinic

Diabetes Care | March 5, 2007 | Volume: 23 | Issue: 9 | Pages: 1407-1415

10.2337/diacare.23.9.1407 | PMID 10977042 Get It

OBJECTIVE: To determine the effects of fish oil supplementation on lipid levels and glycemic control in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: A comprehensive search of Medline, Embase, Lilacs, the Cochrane Clinical Trials Registry bibliographies of relevant papers, and expert input updated through September 1998 was undertaken. All randomized placebo-controlled trials were included in which fish oil supplementation was the only intervention in subjects with type 2 diabetes. Three investigators performed data extraction and quality scoring independently with discrepancies resolved by consensus. Eighteen trials including 823 subjects followed for a mean of 12 weeks were included. Doses of fish oil used ranged from 3 to 18 g/day The outcomes studied were glycemic control and lipid levels. RESULTS: Meta-analysis of pooled data demonstrated a statistically significant effect of fish oil on lowering triglycerides (-0.56 mmol/l [95% CI -0.71 to -0.41]) and raising LDL cholesterol (0.21 mmol/l [0.02 to 0.41]). No statistically significant effect was observed for fasting glucose. HbA1c total cholesterol, or HDL cholesterol. The triglyceride-lowering effect and the elevation in LDL cholesterol were most marked in those trials that recruited hypertriglyceridemic subjects and used higher doses of fish oil. Heterogeneity was observed and explained by the recruitment of subjects with baseline hypertriglyceridemia in some studies. CONCLUSIONS: Fish oil supplementation in type 2 diabetes lowers triglycerides, raises LDL cholesterol, and has no statistically significant effect on glycemic control. Trials with hard clinical end points are needed.
IL1RN VNTR Polymorphism in Ischemic Stroke
Worrall, Bradford B. , Brott, Thomas G. , Brown, Robert D., Brown, W. Mark , Rich, Stephen S. , Arepalli, Sampath, Vrièze, Fabienne Wavrant‐De, Duckworth, Jaime, Singleton, Andrew , Hardy, John , Meschia, James F. , Rich, Stephen S , Hardy, John

Mayo Clinic

Stroke | March 2, 2007 | Volume: 38 | Issue: 4 | Pages: 1189-1196

10.1161/01.str.0000260099.42744.b0 | PMID 17332449 Get It

Background and Purpose— Genetic factors influence risk for ischemic stroke and likely do so at multiple steps in the pathogenic process. Variants in genes related to inflammation contribute to risk of stroke. The purpose of this study was to confirm our earlier finding of an association between allele 2 of a variable number tandem repeat of the IL-1 receptor antagonist gene ( IL1RN ) and cerebrovascular disease. Methods— An association study of the variable number tandem repeat genotype with ischemic stroke and stroke subtypes was performed on samples from a North American study of affected sibling pairs concordant for ischemic stroke and 2 North American cohorts of prospectively ascertained ischemic stroke cases and unrelated controls. DNA analysis was performed on cases and controls, stratified by race. Results— After adjustment for age, sex, and stroke risk factors, the odds ratio for association of allele 2 and ischemic stroke was 2.80 (95% confidence interval, 1.29 to 6.11; P =0.03) for the white participants. The effect of allele 2 of IL1RN on stroke risk most closely fits a recessive genetic model ( P =0.009). For the smaller sample of nonwhite participants, the results were not significant. Conclusions— Allele 2 of IL1RN , present in nearly one-quarter of stroke patients, may contribute to genetic risk for ischemic stroke and confirm the previously identified association with cerebrovascular disease. These results are driven by the association in the white participants. Further exploration in a larger nonwhite sample is warranted.
A buccal mucosa carcinoma treated with high dose rate brachytherapy
Prisciandaro, Joann I. , Foote, Robert L. , Herman, Michael , Lee, Sally J., LaJoie, Wayne N., Blarcom, Andrew B. Van, Yeakel, Peter D.

Mayo Clinic

Journal of Applied Clinical Medical Physics | February 22, 2007 | Volume: 6 | Issue: 1 | Pages: 8-12

10.1120/jacmp.v6i1.2064 | PMID 15770193 Get It

This manuscript presents a case of early stage squamous cell carcinoma of the left buccal mucosa treated with intensity‐modulated radiation therapy (IMRT) followed by a high‐dose rate (HDR) brachytherapy boost. With limited literature available on HDR mold (stent) radiotherapy for oral cancer, a discussion on the issues encountered during treatment planning and delivery may prove to be insightful for facilities faced with a similar challenge.PACS numbers: 87.53.Jw, 87.53.Tf, 87.59.Ci, 87.59.Fm
Identification and Validation of Colorectal Neoplasia–Specific Methylation Markers for Accurate Classification of Disease
Model, Fabian , Osborn, Neal, Ahlquist, David A. , Gruetzmann, Robert, Molnár, Béla , Sípos, Ferenc , Galamb, Orsolya , Pilarsky, Christian , Saeger, Hans-Detlev, Tulassay, Zsolt , Hale, Kari, Lograsso, Joseph, Adorján, Péter, Lesche, Ralf , Dessauer, Andreas, Kleiber, Joerg, Porstmann, B, Sledziewski, Andrew, Lofton–Day, Catherine, Mooney, Suzanne

Mayo Clinic

Molecular Cancer Research | February 21, 2007 | Volume: 5 | Issue: 2 | Pages: 153-163

10.1158/1541-7786.mcr-06-0034 | PMID 17314273 Get It

Abstract Aberrant DNA methylation occurs early in oncogenesis, is stable, and can be assayed in tissues and body fluids. Therefore, genes with aberrant methylation can provide clues for understanding tumor pathways and are attractive candidates for detection of early neoplastic events. Identification of sequences that optimally discriminate cancer from other diseased and healthy tissues is needed to advance both approaches. Using well-characterized specimens, genome-wide methylation techniques were used to identify candidate markers specific for colorectal neoplasia. To further validate 30 of these candidates from genome-wide analysis and 13 literature-derived genes, including genes involved in cancer and others with unknown functions, a high-throughput methylation-specific oligonucleotide microarray was used. The arrays were probed with bisulfite-converted DNA from 89 colorectal adenocarcinomas, 55 colorectal polyps, 31 inflammatory bowel disease, 115 extracolonic cancers, and 67 healthy tissues. The 20 most discriminating markers were highly methylated in colorectal neoplasia (area under the receiver operating characteristic curve > 0.8; P < 0.0001). Normal epithelium and extracolonic cancers revealed significantly lower methylation. Real-time PCR assays developed for 11 markers were tested on an independent set of 149 samples from colorectal adenocarcinomas, other diseases, and healthy tissues. Microarray results could be reproduced for 10 of 11 marker assays, including eight of the most discriminating markers (area under the receiver operating characteristic curve > 0.72; P < 0.009). The markers with high specificity for colorectal cancer have potential as blood-based screening markers whereas markers that are specific for multiple cancers could potentially be used as prognostic indicators, as biomarkers for therapeutic response monitoring or other diagnostic applications, compelling further investigation into their use in clinical testing and overall roles in tumorigenesis. (Mol Cancer Res 2007;5(2):153–63)
Brain protection using autologous bone marrow cell, metalloproteinase inhibitors, and metabolic treatment in cerebral ischemia
Baker, Andrew H. , Sica, Vincenzo, Work, Lorraine M. , Williams‐Ignarro, Sharon, Nigris, Filomena de , Lerman, Lilach O. , Casamassimi, Amelia , Lanza, Alessandro , Schiano, Concetta , Rienzo, Monica , Ignarro, Louis J., Napoli, Claudio , Baker, Andrew H

Mayo Clinic

Proceedings of the National Academy of Sciences | February 21, 2007 | Volume: 104 | Issue: 9 | Pages: 3597-3602

10.1073/pnas.0611112104 | PMID 17360688 Get It

Despite advances in imaging, understanding the underlying pathways, and clinical translation of animal models of disease there remains an urgent need for therapies that reduce brain damage after stroke and promote functional recovery in patients. Blocking oxidant radicals, reducing matrix metalloproteinase-induced neuronal damage, and use of stem cell therapy have been proposed and tested individually in prior studies. Here we provide a comprehensive integrative management approach to reducing damage and promoting recovery by combining biological therapies targeting these areas. In a rat model of transient cerebral ischemia (middle cerebral artery occlusion) gene delivery vectors were used to overexpress tissue inhibitor of matrix metalloproteinase 1 and 2 (TIMP1 and TIMP2) 3 days before ischemia. After occlusion, autologous bone marrow cells alone or in combination with agents to improve NO bioavailability were administered intraarterially. When infarct size, BrdU incorporation, and motor function recovery were determined in the treatment groups the largest beneficial effect was seen in rats receiving the triple combined therapy, surpassing effects of single or double therapies. Our study highlights the utility of combined drug, gene, and cell therapy in the treatment of stroke.
Distinctive MRI findings in pallidopontonigral degeneration (PPND)
Frank, Andrew , Jack, Clifford R. , Wszołek, Zbigniew K. , Boeve, Bradley F. , Jack, Clifford R

Mayo Clinic

Neurology | February 19, 2007 | Volume: 68 | Issue: 8 | Pages: 620-621

10.1212/01.wnl.0000254614.39759.3d | PMID 17310038 Get It

Surgical and Interventional Visceral Revascularization for the Treatment of Chronic Mesenteric Ischemia—When to Prefer Which?
Oldenburg, W. Andrew, Paz‐Fumagalli, Ricardo , McKinney, J. Mark , Hakaim, Albert G., Biebl, Matthias

Mayo Clinic

World Journal of Surgery | February 15, 2007 | Volume: 31 | Issue: 3 | Pages: 562-568

10.1007/s00268-006-0434-5 | PMID 17334867 Get It

AbstractBackgroundThe purpose of the present study was to compare surgical and endovascular revascularization for chronic mesenteric ischemia (CMI).MethodsForty‐nine patients underwent surgical (SG) or endovascular (EG) treatment. Relief of symptoms was considered the primary endpoint; patency, morbidity, and mortality were secondary endpoints. For statistical analysis, significance was assumed if P values ≤ 0.05.ResultsTwenty‐six patients (53%) underwent surgical revascularization; 23 patients (47%), endovascular repair. Mean follow‐up was 25 ± 21 months (SG) versus 10 ± 10 (EG) months (P = 0.07). Except for body mass indices (SG 18.9 ± 2.7 versus EG 23.6 ± 4.8; P = 0.001), preoperative data were comparable. Freedom from symptoms was 100% (SG) versus 90% (EG) after intervention (P = 0.194), and 89% (SG) versus 75% (EG) at the end of follow‐up. Reocclusion or re‐stenosis occurred in 8% (SG) versus 25% (EG) (log‐rank test: P = 0.003), and mesenteric ischemia developed in 0% (SG) versus 9% (EG) (P = 0.04). Reintervention for CMI was required in 0% (SG) versus 13% (EG) (P = 0.01). Surgical patients experienced more early complications (42% versus EG 4%; P = 0.02) and longer hospital stays (11.6 ± 10.9 days versus EG 1.3 ± 0.5 days; P < 0.001). Overall mortality at the end of follow‐up was 31% (SG) versus 4% (EG) (log‐rank test: P = 0.08), including all patients with combined open mesenteric and aortic reconstruction (P = 0.001).ConclusionsSurgical treatment has superior long‐term patency and requires fewer reinterventions, but it is also more invasive with greater morbidity and mortality compared to endovascular treatment. Endovascular techniques may be preferable in patients with significant co‐morbidities, concomitant aortic disease, or indeterminate symptoms.
Lack of aggregation of ischemic stroke subtypes within affected sibling pairs
Wiklund, Per-Gunnar, Brown, W. Mark , Brott, Thomas G. , Brown, Robert D., Nilsson-Ardnor, Sofie, Hardy, John , Kissela, Brett , Singleton, Andrew , Holmberg, Dan , Rich, Stephen S. , Stegmayr, Bernd Georg , Meschia, James F. , Rich, Stephen S , Hardy, John

Mayo Clinic

Neurology | February 5, 2007 | Volume: 68 | Issue: 6 | Pages: 427-431

10.1212/01.wnl.0000252955.17126.6a | PMID 17283317 Get It